The field of obesity and metabolism in endocrine-related cancers is gaining significant attention due to the complex interplay between adipose tissue and tumor biology. Adipose tissue, recognized for its endocrine, metabolic, and immune regulatory roles, is now understood to be a critical player in cancer development and progression. Adipocytes, the primary cells in adipose tissue, not only supply metabolic substrates necessary for cancer cell proliferation but also secrete signaling molecules that enhance tumor cell adhesion, migration, invasion, angiogenesis, and inflammation. This interaction is bidirectional, as cancer cells can reprogram adipocytes to adopt a more inflammatory phenotype, creating a feedback loop that accelerates tumor growth. The prevalence of obesity, a condition linked to increased cancer risk, has risen dramatically worldwide, prompting a surge in research focused on the cellular and molecular mechanisms by which adipocytes and adipose tissue contribute to tumorigenesis. Despite these advances, there remain significant gaps in understanding the precise molecular pathways involved, particularly how diet and lipid metabolism influence cancer risk and progression.
This research topic aims to elucidate the intricate roles of obesity and metabolism in the context of endocrine-related cancers. The primary objectives include investigating the contribution of adipocytes and lipid metabolism to tumor development, understanding the metabolic interactions within the tumor microenvironment, and exploring how these processes affect cancer therapy responsiveness. Key questions include how obesity exacerbates cancer risk and progression, and the potential for metabolism-targeted treatments to improve patient outcomes.
To gather further insights in the intersection of obesity, metabolism, and endocrine-related cancers, we welcome articles addressing, but not limited to, the following themes:
- Adipocytes and lipids involvement in tumor development and progression
- Metabolic coupling between cancer and stromal cells in the tumor microenvironment
- New insights into lipidomics and metabolomics
- The impact of metabolism reprogramming on therapy responsiveness
- Obesity association with the risk of developing endocrine-related tumors
- The role of lipids in ferroptosis-mediated tumor suppression
- Metabolism-targeted treatments and adipocytes-based therapies
- The role of diets with different lipid intakes on the outcomes of patients affected by endocrine-related tumors.
The field of obesity and metabolism in endocrine-related cancers is gaining significant attention due to the complex interplay between adipose tissue and tumor biology. Adipose tissue, recognized for its endocrine, metabolic, and immune regulatory roles, is now understood to be a critical player in cancer development and progression. Adipocytes, the primary cells in adipose tissue, not only supply metabolic substrates necessary for cancer cell proliferation but also secrete signaling molecules that enhance tumor cell adhesion, migration, invasion, angiogenesis, and inflammation. This interaction is bidirectional, as cancer cells can reprogram adipocytes to adopt a more inflammatory phenotype, creating a feedback loop that accelerates tumor growth. The prevalence of obesity, a condition linked to increased cancer risk, has risen dramatically worldwide, prompting a surge in research focused on the cellular and molecular mechanisms by which adipocytes and adipose tissue contribute to tumorigenesis. Despite these advances, there remain significant gaps in understanding the precise molecular pathways involved, particularly how diet and lipid metabolism influence cancer risk and progression.
This research topic aims to elucidate the intricate roles of obesity and metabolism in the context of endocrine-related cancers. The primary objectives include investigating the contribution of adipocytes and lipid metabolism to tumor development, understanding the metabolic interactions within the tumor microenvironment, and exploring how these processes affect cancer therapy responsiveness. Key questions include how obesity exacerbates cancer risk and progression, and the potential for metabolism-targeted treatments to improve patient outcomes.
To gather further insights in the intersection of obesity, metabolism, and endocrine-related cancers, we welcome articles addressing, but not limited to, the following themes:
- Adipocytes and lipids involvement in tumor development and progression
- Metabolic coupling between cancer and stromal cells in the tumor microenvironment
- New insights into lipidomics and metabolomics
- The impact of metabolism reprogramming on therapy responsiveness
- Obesity association with the risk of developing endocrine-related tumors
- The role of lipids in ferroptosis-mediated tumor suppression
- Metabolism-targeted treatments and adipocytes-based therapies
- The role of diets with different lipid intakes on the outcomes of patients affected by endocrine-related tumors.